The Life Sciences IPOs + Capital Markets team advised Goldman Sachs & Co. LLC and the other underwriters of Arvinas, Inc.’s (Nasdaq: ARVN) public offering of 5,714,286 shares of its common stock at a price of $70 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to an additional 857,142 shares of common stock at the public offering price, less the underwriting discounts and commissions.
Arvinas is a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine.
The Goodwin team was led by Rob Puopolo, Seo Salimi, Will Magioncalda, and Peter Rodas, and included Stephanie Philbin, Steven Tjoe, and Olivia Uitto.
For more details, read the press release and articles from S&P Global and Seeking Alpha.